
A study involving 2,494 heart failure (HF) patients with end-stage kidney disease (ESKD) on dialysis demonstrated that Angiotensin Receptor-Neprilysin Inhibitors (ARNI) significantly enhanced left ventricular ejection fraction (LVEF) by 8.05% and reduced all-cause mortality (risk ratio 0.64). ARNI treatment also improved left ventricular remodelling, including reductions in left ventricular end-systolic diameter and left atrial diameter, without significantly increasing the risk of severe hyperkalaemia or symptomatic hypotension. The benefits were most notable in patients with HF with reduced ejection fraction. Despite these improvements, ARNI did not significantly reduce hospitalizations for heart failure.
Like
Save
Share